DMT
DMT is a naturally occurring psychedelic of the tryptamine class, found widely throughout the plant and animal kingdoms, including in trace amounts in humans.123 Richard Manske first synthesized it in 1931, and South American entheogenic traditions have used it for millennia.4 When vaporized, DMT produces an exceptionally intense but brief psychedelic experience.41 It can also be taken orally alongside a monoamine oxidase inhibitor, as in traditional ayahuasca preparations.5
Contents
Dosage & Duration
Dosage
These dosage values assume complete vaporization efficiency. In practice, most vaporization techniques do not achieve full efficiency, so actual doses may need adjustment. The probability of a breakthrough experience increases at higher doses. Caution is advised when approaching higher dosage ranges. Start lower to reduce risk of taking too much.
Duration
Subjective Effects
Effects vary widely by individual, dose, and context.
Physical
Cognitive
The head space of DMT is described by most as extremely sober and clear headed in its style when compared to other commonly used psychedelics such as LSD, psilocin or even ayahuasca. It contains a limited amount of typical cognitive effects. DMT in its smokeable form is perhaps the least psychologically intoxicating psychedelic, leading many people to describe it not as a drug induced trip but a genuine experience that is actually happening to them.
Progressive Stages
The first step of a DMT trip is the come up that leads onto breaking through. A person notices an extremely distinct set of visual enhancements, most notably an increase in visual acuity and colour intensity. This is followed by a sudden onset of high level geometry, the body high, and the feeling of your body being pleasantly tugged in all directions at once from the inside. This is often accompanied by a soft crackling sound and an extended tone that quickly increases in volume and pitch.
Almost immediately after taking off, trippers often find themselves spending a brief amount of time in what feels like a psychedelic 'waiting room' or 'loading screen'. This can take any form but generally takes the shape of a tunnel or space comprised of fast moving geometry that lasts approximately 10-20 seconds and feels distinctively different from the main bulk of the trip.
Once the waiting period is over, the user will feel that they have broken through onto the other side. This is visiting an alternate reality that feels so real it seems to be better defined than real life, usually with a single or multiple external autonomous entities in front of your line of sight. These entities appear to have been waiting for your arrival, usually completely unsurprised by the tripper's sudden appearance.
The final stage is experienced as the sensation of being pulled further and further away from the scenario in which you were placed as the entities often wave goodbye and encourage you to come back when you next get the chance.
Visual
Geometry
The geometry present with smokeable DMT is often considered to be the most profoundly intricate and complex set of visual geometry found within the entirety of the psychedelic experience. In comparison to orally active DMT (ayahuasca) they are significantly more digital in appearance and contain a colour scheme which is similar to LSD but a structured style that is closer to high dose psilocin.
Hallucinatory States
DMT produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of any other commonly used psychedelic.
Auditory
Reagent Testing
Loading reagent data
Pharmacology
Pharmacodynamics
DMT acts primarily through agonism at the serotonin 5-HT2A receptor, which is considered the principal mediator of its psychedelic effects.2 It has been characterized as a partial and biased agonist at this site, activating the Gq signaling pathway without significantly recruiting β-arrestin2.2 DMT also acts as an agonist at 5-HT1A and 5-HT2C receptors and shows broad, non-selective binding across numerous additional serotonin subtypes.2 It is additionally a potent serotonin releasing agent and functions as an agonist at sigma-1 and trace amine-associated receptor 1 (TAAR1), with further affinity demonstrated at dopamine D1, adrenergic, and imidazoline-1 receptors.2
Pharmacokinetics
DMT is rapidly metabolized by monoamine oxidase A (MAO-A), rendering it orally inactive unless combined with a monoamine oxidase inhibitor.25 The primary metabolic product is indole-3-acetic acid, with DMT-N-oxide as a notable secondary metabolite.62 Additional pathways include N-dealkylation and cyclization to β-carbolines. To a lesser extent, CYP2D6 and CYP2C19 contribute to hepatic metabolism; when smoked, a more substantial fraction (possibly 10–20%) is processed through these enzymes. Following intravenous administration, DMT has a plasma half-life of approximately 9–12 minutes and can become undetectable in blood within about one hour.6 DMT readily crosses the blood-brain barrier and has been observed to accumulate in brain tissue following peripheral administration in animal models.2
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Tolerance
Serotonergic psychedelics (limited; research from the 1970s found LSD-tolerant individuals showed minimal cross-tolerance to DMT)
Harm Potential
Addiction & Dependence
Psychological
Extremely LowDMT is considered non-addictive with low abuse potential.7 Many users report a self-regulating quality to the substance, and studies examining substance use disorder found almost no hallucinogens produced dependence.8
Physical
Extremely LowNo physical dependence or withdrawal syndrome has been documented with DMT use.7 The physiological dependence potential appears minimal when used infrequently.
Toxicity
Psychosis Risk
DMT can trigger psychological reactions including intense fear, paranoia, anxiety, panic attacks, and substance-induced psychosis, particularly in predisposed individuals.11 Latent psychoses may be triggered, and permanent disturbances in self- and reality-recognition are possible in vulnerable populations. Case reports describe temporary psychotic episodes that typically resolved within weeks,7 though individuals with personal or family history of psychotic illness appear at elevated risk.
Seizure Risk
Seizure risk from DMT alone appears minimal; documented seizure concerns primarily involve drug combinations, particularly with lithium or tramadol.12
History & Culture
Trip Reports
Loading related reports
Preparing section content
Still loading. Refresh if this section does not appear.
Legality
International
UN Convention on Psychotropic Substances 1971 (Schedule I)
By Country
References
Source Pages
Citations
- Drug Enforcement Administration, Diversion Control Division, Drug & Chemical Evaluation Section. (December 2025). N,N-Dimethyltryptamine (DMT). U.S. Drug Enforcement Administration. https://deaecom.gov/drug_chem_info/dmt.pdf12
- Carbonaro TM, & Gatch MB. (September 2016). Neuropharmacology of N,N-dimethyltryptamine. Brain Research Bulletin, 126, 74–88. https://doi.org/10.1016/j.brainresbull.2016.04.01612345678910
- Dean JG, Liu T, Huff S, Sheler B, Barker SA, Strassman RJ, Wang MM, & Borjigin J. (June 2019). Biosynthesis and Extracellular Concentrations of N,N-Dimethyltryptamine (DMT) in Mammalian Brain. Scientific Reports, 9, Article 9333. https://doi.org/10.1038/s41598-019-45812-w1
- (n.d.). DMT. UC Berkeley Center for the Science of Psychedelics. https://psychedelics.berkeley.edu/substance/dmt/123456
- (n.d.). Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors. Cellular and Molecular Life Sciences, 81(1), Article 395. https://doi.org/10.1007/s00018-024-05353-612
- (January 2024). Psychological and physiological effects of extended DMT. Journal of Psychopharmacology, 38(1), 56–67. https://doi.org/10.1177/0269881123119687712
- (January 2007). Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. Addiction, 102(1), 24–34. https://doi.org/10.1111/j.1360-0443.2006.01652.x123
- (2019). Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness. Current Neuropharmacology, 17(2), 1–15. https://doi.org/10.2174/1570159x166661801250959021
- Tagen M, Mantuani D, van Heerden L, Holstein A, Klumpers LE, & Knowles R. (September 2023). The risk of chronic psychedelic and MDMA microdosing for valvular heart disease. Journal of Psychopharmacology, 37(9), 876–890. https://doi.org/10.1177/0269881123119086512
- (June 2025). Repeated and one-time administration of DMT produces marked changes in the cardiovascular system,<ref name="pmid28868040" /> with an increase in systolic and diastolic blood pressu. https://doi.org/10.1007/s0021300006061
- (n.d.). Neurobiologist [[Andrew Gallimore]] suggested in 2013 that while DMT might not have a modern neural function, it may have been an ancestral neuromodulator once secreted in psychede. https://doi.org/10.3389/fpsyt.2017.001521
- (1 October 2022). Prevalence and associations of classic psychedelic-related seizures in a population-based sample. Drug and Alcohol Dependence, 239. https://doi.org/10.1016/j.drugalcdep.2022.1095861
- (June 2019). Chemical evidence for the use of multiple psychotropic plants in a 1,000-year-old ritual bundle from South America. Proceedings of the National Academy of Sciences of the United States of America, 116(23), 11207–11212. https://doi.org/10.1073/pnas.19021741161
- (2022-03-11). Szara, Stephen. Center for the Study of the History of Neuropsychopharmacology. https://cshn.semel.ucla.edu/2022/03/11/szara-stephen/1
- Supreme Court of the United States. (2006). Gonzales v. O Centro Espírita Beneficente União do Vegetal, 546 U.S. 418 (2006). https://www.law.cornell.edu/supct/html/04-1084.ZO.html1
- (2001). DMT: The Spirit Molecule. A Doctor's Revolutionary Research into the Biology of Near-Death and Mystical Experiences. Park Street. https://archive.org/details/dmtspiritmolecul00rick12
- (n.d.). Primary legal source. legislation.gov.au. https://www.legislation.gov.au/F2026L00633/asmade/2026-05-28/text/original/epub/OEBPS/document_1/document_1.html1
- (n.d.). Primary legal source. ris.bka.gv.at. https://ris.bka.gv.at/NormDokument.wxe?Abfrage=Bundesnormen&Anlage=5&Artikel=&FassungVom=2026-02-05&Gesetzesnummer=10011053&Paragraf=&ShowPrintPreview=True&Uebergangsrecht=1
- (n.d.). Primary legal source. afmps.be. https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf1
- (n.d.). Primary legal source. ejustice.just.fgov.be. https://www.ejustice.just.fgov.be/cgi/article_body.pl?language=fr&caller=summary&pub_date=17-09-26&numac=20170312311
- (n.d.). Primary legal source. bvsms.saude.gov.br. https://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2010/rdc0021_17_06_2010.html1
- (n.d.). Primary legal source. pesquisa.in.gov.br. https://pesquisa.in.gov.br/imprensa/servlet/INPDFViewer?captchafield=firstAccess&data=26%2F01%2F2010&jornal=1&pagina=571
- (n.d.). Primary legal source. gov.br. https://www.gov.br/mj/pt-br/acesso-a-informacao/perguntas-frequentes/drogas/conselho-nacional-de-politicas-sobre-drogas1
- (n.d.). Primary legal source. laws-lois.justice.gc.ca. https://laws-lois.justice.gc.ca/eng/acts/c-38.8/FullText.html1
- Government of Canada. (n.d.). Controlled Drugs and Substances Act, Schedule III – N,N-Dimethyltryptamine (item 7). https://laws-lois.justice.gc.ca/eng/acts/c-38.8/section-sched95602-20031211.html1
- (n.d.). Primary legal source. bcn.cl. https://www.bcn.cl/leychile/Navegar?idNorma=2693231
- (n.d.). Primary legal source. bcn.cl. https://www.bcn.cl/leychile/Navegar?idNorma=269323&idParte=8376716&idVersion=2022-09-131
- (n.d.). Primary legal source. suin-juriscol.gov.co. https://www.suin-juriscol.gov.co/viewDocument.asp?id=10266611
- (n.d.). Primary legal source. mincit.gov.co. https://www.mincit.gov.co/ministerio/normograma-sig/procesos-misionales/facilitacion-del-comercio-y-defensa-comercial/circulares/2016/anexo-3.aspx1
- (n.d.). Primary legal source. esipa.cz. https://esipa.cz/files/get?uuid=99dd7f4f7325334902b9e9fc1109064c057208dc786b2ebd205ac6fa4850fc80357fcb650d9416ffb35a9d48bda12c965ee306ce7a392addf77760dc25d02f3c1
- (n.d.). Primary legal source. mzd.gov.cz. https://mzd.gov.cz/wp-content/uploads/2025/10/Sb_1998_167_2026-01-01_IZ.pdf1
- (n.d.). Primary legal source. e-sbirka.gov.cz. https://e-sbirka.gov.cz/sb/2009/401
- (n.d.). Primary legal source. e-sbirka.gov.cz. https://e-sbirka.gov.cz/sb/2013/463/2022-07-011
- (n.d.). Primary legal source. retsinformation.dk. https://www.retsinformation.dk/eli/lta/2026/4051
- (n.d.). Primary legal source. retsinformation.dk. https://www.retsinformation.dk/eli/lta/2026/405/pdf1
- (n.d.). Primary legal source. legifrance.gouv.fr. https://www.legifrance.gouv.fr/loda/id/JORFTEXT000000533085/2025-02-061
- (n.d.). Primary legal source. gesetze-im-internet.de. https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html1
- (n.d.). Primary legal source. gesetze-im-internet.de. https://www.gesetze-im-internet.de/btmg_1981/__3.html1
- (n.d.). Primary legal source. indiacode.nic.in. https://www.indiacode.nic.in/bitstream/123456789/6834/1/narcotic-drugs-and-psychotropic-substances-act-1985.pdf1
- (n.d.). Primary legal source. irishstatutebook.ie. https://www.irishstatutebook.ie/eli/2022/si/211/made/en/print1
- (n.d.). Primary legal source. irishstatutebook.ie. https://www.irishstatutebook.ie/eli/1977/act/12/enacted/en/html1
- (n.d.). Primary legal source. gazzettaufficiale.it. https://www.gazzettaufficiale.it/do/atto/serie_generale/caricaPdf?art.codiceRedazionale=20A03622&art.dataPubblicazioneGazzetta=2020-07-13&art.num=2&art.tiposerie=SG&cdimg=20A0362200400020110001&dgu=2020-07-131
- (n.d.). Primary legal source. mhlw.go.jp. https://www.mhlw.go.jp/content/11120000/001334618.pdf1
- (n.d.). Primary legal source. mhlw.go.jp. https://www.mhlw.go.jp/web/t_doc?dataId=811051001
- (n.d.). Primary legal source. diputados.gob.mx. https://www.diputados.gob.mx/LeyesBiblio/pdf/LGS.pdf1
- (n.d.). Primary legal source. wetten.overheid.nl. https://wetten.overheid.nl/BWBR0001941?g=2017-05-25&labelid=2936994&z=2026-01-251
- Parliamentary Counsel Office (New Zealand). (n.d.). Misuse of Drugs Act 1975, Schedule 1: Class A controlled drugs. https://www.legislation.govt.nz/act/public/1975/0116/latest/DLM436576.html12
- (n.d.). Primary legal source. legislation.govt.nz. https://www.legislation.govt.nz/act/public/1975/0116/latest/LMS9604.html1
- (n.d.). Primary legal source. lovdata.no. https://lovdata.no/dokument/SF/forskrift/2013-02-14-199/KAPITTEL_11
- (n.d.). Primary legal source. lovdata.no. https://lovdata.no/dokument/SF/forskrift/2013-02-14-199/%C2%A771
- (n.d.). Primary legal source. elibrary.judiciary.gov.ph. https://elibrary.judiciary.gov.ph/thebookshelf/showdocs/2/14351
- (n.d.). Primary legal source. issuances-library.senate.gov.ph. https://issuances-library.senate.gov.ph/legislative%2Bissuances/Republic%20Act%20No.%2091651
- (n.d.). Primary legal source. eli.gov.pl. https://eli.gov.pl/api/acts/DU/2024/1139/text.html1
- (n.d.). Primary legal source. ips.pravo.gov.ru. https://ips.pravo.gov.ru/api/ips/legislation/document?baseid=None&hash=4f3e2b09ec67c44a6cf6a43dadfa2bb8f18b308deee875a951cc59a78f8eb6501
- (n.d.). Primary legal source. sso.agc.gov.sg. https://sso.agc.gov.sg/Act/MDA1973?ProvIds=Sc1-1
- (n.d.). Primary legal source. cnb.gov.sg. https://www.cnb.gov.sg/singapore-drug-situation/misuse-of-drugs-act/1
- (n.d.). Primary legal source. customs.go.kr. https://www.customs.go.kr/kcs/cm/cntnts/cntntsView.do?cntntsId=7641&mi=138061
- (n.d.). Primary legal source. mfds.go.kr. https://www.mfds.go.kr/wpge/m_736/de010114l001.do1
- (n.d.). Primary legal source. boe.es. https://www.boe.es/eli/es/rd/1977/10/06/2829/con1
- (n.d.). Primary legal source. swissmedic.ch. https://www.swissmedic.ch/dam/swissmedic/en/dokumente/bewilligungen/btm/praezisierung_vonswissmediczumbetaeubungsmittelrechtlichenstatus.pdf.download.pdf/praezisierung_vonswissmediczumbetaeubungsmittelrechtlichenstatus.pdf1
- (n.d.). Primary legal source. ratchakitcha.soc.go.th. https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0007.PDF1
- (n.d.). Primary legal source. narcotic.fda.moph.go.th. https://narcotic.fda.moph.go.th/law-type/pc-1851
- (n.d.). Primary legal source. narcotic.fda.moph.go.th. https://narcotic.fda.moph.go.th/information-about-drugs/detail-ps1
- (n.d.). Primary legal source. narcotic.fda.moph.go.th. https://narcotic.fda.moph.go.th/penalty-narco-phycho-volatile-head/category/penalty-psycho-11
- (n.d.). Primary legal source. permitfortraveler.fda.moph.go.th. https://permitfortraveler.fda.moph.go.th/nct_permit_main/Upload/PHYCHO_list_update_25_07_2025.pdf1
- (n.d.). Primary legal source. resmigazete.gov.tr. https://www.resmigazete.gov.tr/eskiler/2015/02/20150206.htm1
- (n.d.). Primary legal source. alternatifcozumler.adalet.gov.tr. https://alternatifcozumler.adalet.gov.tr/Resimler/icon/230620251139455237%20Say%C4%B1l%C4%B1%20T%C3%BCrk%20Ceza%20Kanunu%20i%C3%A7in%20TIKLAYINIZ..pdf1
- (n.d.). Primary legal source. zakon.rada.gov.ua. https://zakon.rada.gov.ua/go/770-2000-%D0%BF1
- (n.d.). Primary legal source. u.ae. https://u.ae/-/media/Information-and-services/Health/Annex-to-travelers-guidelines-1.ashx1
- (n.d.). Primary legal source. u.ae. https://u.ae/ar/information-and-services/health-and-fitness/drugs-and-controlled-medicines1
- (n.d.). Primary legal source. legislation.gov.uk. https://www.legislation.gov.uk/ukpga/1971/38/schedule/21
- (n.d.). Primary legal source. legislation.gov.uk. https://www.legislation.gov.uk/ukpga/1971/38/pdfs/ukpga_19710038_en.pdf1
- UK Parliament. (n.d.). Misuse of Drugs Act 1971, Schedule 2 Part I – Class A drugs. https://www.legislation.gov.uk/ukpga/1971/38/schedule/2/enacted1
- (n.d.). Primary legal source. govinfo.gov. https://www.govinfo.gov/link/cfr/21/1308?link-type=pdf&year=mostrecent1
- (n.d.). Primary legal source. supremecourt.gov. https://www.supremecourt.gov/opinions/boundvolumes/546bv.pdf1
- United States Congress. (n.d.). 21 U.S. Code § 812 – Schedules of controlled substances, Schedule I(c)(5). https://www.law.cornell.edu/uscode/text/21/8121
- Supreme Court of the United States. (n.d.). Gonzales v. O Centro Espírita Beneficente União do Vegetal, 546 U.S. 418 (2006). https://caselaw.findlaw.com/court/us-supreme-court/546/418.html1
- (n.d.). Primary legal source. content.leg.colorado.gov. https://content.leg.colorado.gov/sites/default/files/documents/2023A/bills/sl/2023a_sl_249.pdf1
- (n.d.). Primary legal source. cbi.colorado.gov. https://cbi.colorado.gov/sections/biometric-identification-and-records-unit/natural-medicine-pardons1
- (n.d.). Primary legal source. code.dccouncil.gov. https://code.dccouncil.gov/us/dc/council/code/sections/48-902.041
- (n.d.). Primary legal source. code.dccouncil.gov. https://code.dccouncil.gov/us/dc/council/code/sections/48-921.521
Further Reading
Chacruna - DMT and serotonin syndrome risks
dos Santos et al. - Ayahuasca risks review (2016)
Mind Foundation - Psychedelic-Antidepressant Interactions
Nichols DE - Psychedelics review (2016)
PMC: Drug-drug interactions involving classic psychedelics
PubChem: N,N-Dimethyltryptamine (CID 6089)
Spiers et al. - Continuous DMT infusion study (2024)
Spirit Pharmacist - Healing States or Serotonin Toxicity
Strassman RJ - Dose-response study in humans (1994)
Timmermann et al. - DMT models near-death experience (2018)
- Reviewed & approved
Reviewed, edited, and approved by subject-matter expert Lyrea.
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the DMT article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.